AG2304R

Ahn-Gook Pharmaceuticals Co.,Ltd · Phase 3 active Small molecule

AG2304R is an investigational therapeutic in phase 3 development by Ahn-Gook Pharmaceuticals with an undisclosed mechanism of action.

At a glance

Generic name	AG2304R
Sponsor	Ahn-Gook Pharmaceuticals Co.,Ltd
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Limited public information is available regarding the specific molecular mechanism of AG2304R. As a phase 3 candidate from Ahn-Gook Pharmaceuticals, it has progressed through early clinical development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AG2304R CI brief — competitive landscape report
AG2304R updates RSS · CI watch RSS
Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI